AU2021277373A1 - Potent neutralizing antibodies against SARS-CoV-2, generation and uses thereof - Google Patents

Potent neutralizing antibodies against SARS-CoV-2, generation and uses thereof Download PDF

Info

Publication number
AU2021277373A1
AU2021277373A1 AU2021277373A AU2021277373A AU2021277373A1 AU 2021277373 A1 AU2021277373 A1 AU 2021277373A1 AU 2021277373 A AU2021277373 A AU 2021277373A AU 2021277373 A AU2021277373 A AU 2021277373A AU 2021277373 A1 AU2021277373 A1 AU 2021277373A1
Authority
AU
Australia
Prior art keywords
seq
polypeptide sequence
cdr2
cdr1
cdr3
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2021277373A
Other languages
English (en)
Inventor
David D. Ho
Yaoxing Huang
Lihong Liu
Yang Luo
Manoj S. Nair
Pengfei Wang
Jian Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University in the City of New York
Original Assignee
Columbia University in the City of New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University in the City of New York filed Critical Columbia University in the City of New York
Publication of AU2021277373A1 publication Critical patent/AU2021277373A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • AIDS & HIV (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2021277373A 2020-05-20 2021-05-20 Potent neutralizing antibodies against SARS-CoV-2, generation and uses thereof Abandoned AU2021277373A1 (en)

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202063027935P 2020-05-20 2020-05-20
US63/027,935 2020-05-20
US202063032518P 2020-05-29 2020-05-29
US63/032,518 2020-05-29
US202063039977P 2020-06-16 2020-06-16
US63/039,977 2020-06-16
US202063060116P 2020-08-02 2020-08-02
US63/060,116 2020-08-02
US202063063106P 2020-08-07 2020-08-07
US63/063,106 2020-08-07
US202063117908P 2020-11-24 2020-11-24
US63/117,908 2020-11-24
US202063123767P 2020-12-10 2020-12-10
US63/123,767 2020-12-10
US202163165729P 2021-03-24 2021-03-24
US63/165,729 2021-03-24
PCT/US2021/033512 WO2021236997A2 (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against sars-cov-2, generation and uses thereof

Publications (1)

Publication Number Publication Date
AU2021277373A1 true AU2021277373A1 (en) 2023-01-05

Family

ID=78707603

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021277373A Abandoned AU2021277373A1 (en) 2020-05-20 2021-05-20 Potent neutralizing antibodies against SARS-CoV-2, generation and uses thereof

Country Status (13)

Country Link
US (3) US20230203134A1 (https=)
EP (1) EP4153625A4 (https=)
JP (1) JP2023526469A (https=)
KR (1) KR20230024904A (https=)
AU (1) AU2021277373A1 (https=)
BR (1) BR112022023467A2 (https=)
CA (1) CA3184184A1 (https=)
CL (1) CL2022003215A1 (https=)
CO (1) CO2022018192A2 (https=)
IL (1) IL298263A (https=)
MX (1) MX2022014420A (https=)
PH (1) PH12022500025A1 (https=)
WO (4) WO2021236997A2 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20240182T1 (hr) 2020-03-26 2024-04-26 Vanderbilt University Ljudska monoklonska protutijela za teški akutni respiratorni sindrom koronavirusa 2 (sars-cov-2)
EP4153625A4 (en) * 2020-05-20 2024-09-25 The Trustees Of Columbia University In The City Of New York STRONG NEUTRALISING ANTIBODIES AGAINST SARS-COV-2, THEIR PRODUCTION AND USE
WO2024089277A2 (en) * 2022-10-27 2024-05-02 Oxford University Innovation Limited Antibodies

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1778283A2 (en) * 2004-06-30 2007-05-02 ID Biomedical Corporation of Quebec Vaccine compositions for treating coronavirus infection
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
CA2662350A1 (en) * 2006-09-05 2008-03-13 Medarex, Inc. Antibodies to bone morphogenic proteins and receptors therefor and methods for their use
US7982016B2 (en) * 2007-09-10 2011-07-19 Amgen Inc. Antigen binding proteins capable of binding thymic stromal lymphopoietin
EP2242768A4 (en) * 2008-01-17 2012-03-14 Humabs Llc CROSS-NEUTRALIZATION OF HUMAN MONOCLONAL ANTIBODIES AGAINST SARS-COV AND METHODS FOR THEIR APPLICATION
CN108610416B (zh) * 2008-10-13 2022-01-14 生物医学研究所 登革热病毒中和抗体及其用途
CA2742969A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
CA2932405A1 (en) * 2013-12-02 2015-06-11 Aaron Diamond Aids Research Center Improved hiv-1-neutralizing antibody potency and breadth via cell receptor anchoring using bispecific antibodies with native architecture
WO2016138160A1 (en) * 2015-02-24 2016-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Middle east respiratory syndrome coronavirus immunogens, antibodies, and their use
WO2016187220A2 (en) * 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies
EP3356415B1 (en) * 2015-09-29 2024-05-01 Amgen Inc. Asgr inhibitors for reduzing cholesterol levels
CR20180365A (es) * 2015-12-16 2018-09-28 Amgen Inc PROTEÍNAS DE UNIÓN AL ANTÍGENO BISPECÍFICO DE ANTI-TL1A/ANTI-TNF-a Y SUS USOS
TWI848953B (zh) * 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CN113056483B (zh) * 2018-07-09 2025-08-01 戊瑞治疗有限公司 结合到ilt4的抗体
EP4153625A4 (en) * 2020-05-20 2024-09-25 The Trustees Of Columbia University In The City Of New York STRONG NEUTRALISING ANTIBODIES AGAINST SARS-COV-2, THEIR PRODUCTION AND USE

Also Published As

Publication number Publication date
US20230203134A1 (en) 2023-06-29
WO2021236998A3 (en) 2021-12-16
CL2022003215A1 (es) 2023-07-07
CA3184184A1 (en) 2021-11-25
US20240002476A1 (en) 2024-01-04
BR112022023467A2 (pt) 2023-03-28
WO2021236995A3 (en) 2022-09-15
WO2021236998A2 (en) 2021-11-25
JP2023526469A (ja) 2023-06-21
EP4153625A4 (en) 2024-09-25
WO2021236997A3 (en) 2022-09-29
WO2021236996A3 (en) 2022-11-17
KR20230024904A (ko) 2023-02-21
MX2022014420A (es) 2023-03-21
IL298263A (en) 2023-01-01
WO2021236996A2 (en) 2021-11-25
WO2021236997A2 (en) 2021-11-25
CO2022018192A2 (es) 2023-03-17
WO2021236995A2 (en) 2021-11-25
PH12022500025A1 (en) 2024-03-25
EP4153625A2 (en) 2023-03-29
WO2021236998A9 (en) 2022-03-31
US20230203138A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
JP7684379B2 (ja) 抗ｓａｒｓ－ｃｏｖ－２－スパイク糖タンパク質抗体および抗原結合断片
JP6979875B2 (ja) チクングニヤウイルスの抗体媒介性中和
US20230348572A1 (en) Single domain antibodies binding to sars-cov-2 spike protein
AU2021277373A1 (en) Potent neutralizing antibodies against SARS-CoV-2, generation and uses thereof
Liu et al. Potent Neutralizing Monoclonal Antibodies Directed to Multiple Epitopes on the SARS-CoV-2 Spike
US20240101645A1 (en) Monoclonal antibodies against coronaviruses and uses thereof
EP4206224A1 (en) Human antibody or antigen-binding fragment thereof against coronavirus spike protein
EP4585687A1 (en) Human antibody against coronavirus variants or antigen-binding fragment thereof
CN115087667B (zh) 特异性结合SARS-CoV-2的抗原结合蛋白
CN116829177A (zh) 抗SARS-CoV-2的有效中和抗体及其生成和用途
WO2022095968A1 (en) ANTIBODIES AGAINST SARS-CoV-2 SPIKE PROTEIN
EP3180024B1 (en) Anti-ospa antibodies and methods of use
US20240287161A1 (en) Antibody against coronavirus
WO2025083216A1 (en) Antibodies specific for the spike protein of sars cov-2 coronavirus
WO2024168061A2 (en) Antibody molecules binding to sars-cov-2
WO2024089277A2 (en) Antibodies
WO2023025813A1 (en) Neutralizing antibodies directed to sars-cov-2 spike protein
CN117343168A (zh) 冠状病毒结合分子及医药用途
EP4255487A1 (en) Polypeptides for detection and treatment of coronavirus infection

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period